Combination Almost Doubles Survival in Untreated Mesothelioma

(MedPage Today) -- Survival in patients with malignant pleural mesothelioma (MPM) almost doubled versus historical rates with the immune checkpoint inhibitor durvalumab (Imfinzi) and pemetrexed (Alimta) chemotherapy, a small clinical trial showed...